Clinical TrialJul 27, 2026, 07:02 AM
Neumora Reports Favorable NMRA-215 Toxicology; IND Filing Q4 2026
AI Summary
Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease. A repeat 13-week rat study found no adverse findings, addressing previous discrepancies from an audited study. The company plans to submit an Investigational New Drug (IND) application for NMRA-215 in Q4 2026, aiming to initiate clinical studies in 2026.
Key Highlights
- Neumora reported favorable pre-clinical toxicology results for NMRA-215.
- A repeat 13-week rat toxicology study in 162 animals showed no unexpected adverse findings.
- Prior adverse findings in 5 of 142 animals were attributed to study discrepancies after an audit.
- Neumora plans to submit an IND application for NMRA-215 in the fourth quarter of 2026.
- NMRA-215 is a brain-penetrant oral NLRP3 inhibitor for obesity and cardiometabolic disease.
- Pre-clinical efficacy showed class-leading weight loss as monotherapy and additive effect with semaglutide.
- The company anticipates initiating a clinical study for NMRA-215 in 2026.
Price Impact
More from NMRA